ΜΟΛΙΣ ΕΚΔΟΘΗΚΕ Η ΝΕΑ Κ.Υ.Α. ΓΙΑ ΤΑ ΦΑΡΜΑΚΕΙΑ (Γ5(β)/Γ.Π.οικ.6915/28-01-2016)

Εκδόθηκε η νέα Κ.Υ.Α. από τον κ. Υπουργό Υγείας που  τροποποιεί μερικά την Κ.Υ.Α. Γ.Π.οικ.82829/29-10-2015 (ΦΕΚ 2330 τ. Β’) Δημοσιεύεται εντός ολίγου στο ΦΕΚ.

Σύμφωνα με τις τροποποιήσεις:

Ο υπολογισμός των κενών θέσεων φαρμακείων γίνεται με βάση τις ισχύουσες ρυθμίσεις του άρθρου 36 παρ. 3 του Ν. 3918/2011, ΟΧΙ με την διάταξη του άρθρου 2 παρ. 3 της Κ.Υ.Α. 82829/29-10-2015, η οποία καταργείται.

Επομένως ο υπολογισμός των κενών θέσεων γίνεται με βάση τον πληθυσμό των επιμέρους εδαφικών περιοχών των Δημοτικών Ενοτήτων των Δήμων και την αναλογία ένα φαρμακείο ανά χίλιους κατοίκους ΚΑΙ ΟΧΙ ΜΕ ΒΑΣΗ ΤΟΝ ΠΛΗΘΥΣΜΟ ΤΩΝ ΔΗΜΩΝ που όριζε η καταργηθείσα διάταξη της παραπάνω Κ.Υ.Α.

Which countries get the best - and worst - value healthcare?

By Mark Britnell*

As the world's attention turns to Davos, many people will remark on the Swiss knack for well-functioning services. It’s something I’ve often observed in their health system, which is one of the best I have ever encountered across the world.

You might expect that, considering how much the Swiss pay for healthcare - $9,276 per person, according to the World Bank, or around 11.5% of their total GDP. What fascinates me are those countries that seem to get the same results for a quarter or even less of that cost. For example, Hong Kong ($1,716 per person, 6% GDP), Israel ($2599 per person, 7.2% GDP) and Singapore ($2,507, 4.6% GDP) all of which, like Switzerland, enjoy life expectancies of between 82 and 83 years.

So why is it that some health systems are getting so much more for their money than others?

Although factors like diet and active lifestyles have an influence, it’s also clear that the huge differences in the way different healthcare systems are set up plays a major role too. Why else would we see similar variation in the outcomes of people who undergo certain treatments?

Having worked in sixty countries’ health systems over the past six years, I’ve gained first-hand experience of healthcare in many of these ‘outlier’ countries (both the highly efficient and the highly inefficient). While it’s impossible to say that any one country is best, a look beneath the statistics reveals some of the things most likely to produce more health for less cost.

Top pharma list of TV ad spenders for 2015

 Fierce PharmaMarketing | By Beth Snyder Bulik

Pfizer ($PFE) owned TV ad spending for 2015 among pharma brands. It took 5 spots on the top 10 list for the year, including Nos. 1 and 2, according to iSpot.tv estimated spending tallied for FiercePharmaMarketing. Seizure and pain drug Lyrica came in first with $116.2 million spent in 2015, while Pfizer's pneumococcal pneumonia vaccine Prevnar 13 came in at No. 2 with $101.7 million.

The three other Pfizer drugs on the list were anticoagulant Eliquis (No. 5), arthritis fighter Xeljanz (No. 6) and smoking cessation drug Chantix (No. 9), spending $96.7 million, $85.3 million, and $68.5 million respectively, according to iSpot.tv data.

Other Big Pharmas divvied up the remaining spots. Johnson & Johnson's ($JNJ) diabetes drug Invokana was No. 3 at $101.3 million, while AbbVie's ($ABBV) Humira was No. 4. One unfortunate note at No. 10 was Sanofi's ($SNY) epinephrine product Auvi-Q, which spent $54.2 million in TV advertising, only to have to pull all its injectors on worries that they might be delivering incorrect dosages.

Big Pharma: Declaration at the World Economic Forum in Davos

More than 80 leading international pharmaceutical, generics, diagnostics and biotechnology companies, as well as key industry bodies, have come together to call on governments and industry to work in parallel in taking comprehensive action against drug-resistant infections - so-called 'superbugs' - with a joint declaration launched today at the World Economic Forum in Davos, Switzerland. The statement sets out for the first time how governments and industry need to work together to support sustained investment in the new products needed to beat the challenges of rising drug resistance.

The Declaration on Combating Antimicrobial Resistance - drafted and signed by 85 companies and nine industry associations across 18 countries - represents a major milestone in the global response to these challenges, with commercial drug and diagnostic developers for the first time agreeing on a common set of principles for global action to support antibiotic conservation and the development of new drugs, diagnostics, and vaccines. The industry is calling on governments around the world to now go beyond existing statements of intent and take concrete action, in collaboration with companies, to support investment in the development of antibiotics, diagnostics, vaccines, and other products vital for the prevention and treatment of drug-resistant infections.

Pharma reps ready for a change

Fierce Pharma Marketing | Emily Wasserman

Job satisfaction can be elusive, as pharma sales reps know all too well. A new report from MedReps.com, a job board for medical sales reps, shows that while pharma reps and their biotech rep peers are mostly content with their jobs, they're still hankering for a change.

MedReps surveyed more than 1,400 medical sales reps about the best places to work in the industry, tallied results for all the respondents and also broke down the numbers by field. While exactly half of pharma reps said that they are satisfied or somewhat satisfied in their jobs, more than three-quarters, or 76%, of reps said that they are somewhat likely or very likely to leave their jobs in the next year.

Biotech reps had similar qualms. More than half of reps said that they were satisfied or at least somewhat satisfied with their jobs. But a little more than three quarters of biotech reps also said that they would probably leave their job this year. Neither biotech nor pharma reps spelled out exactly why they wanted to leave their current position, though. Nor did they say where they would go once they left.

Διάκριση επιχειρηματικής αριστείας για τη Novartis Hellas

Μια ακόμη σημαντική διάκριση απέσπασε η Novartis Hellas ως επιβράβευση των οικονομικών της δεικτών και των σημαντικών της πρωτοβουλιών. Συγκεκριμένα και βάσει στοιχείων οικονομικού έτους 2014, η Novartis Hellas είναι η πρώτη σε πωλήσεις θυγατρική πολυεθνικής εταιρείας φαρμάκου στην Ελλάδα, και ασκώντας ενεργό ρόλο στον κλάδο της Υγείας, δημιουργεί πρόσθετη υπεραξία και στον τομέα του επιχειρείν. Η βράβευση πραγματοποιήθηκε από τον Οργανισμό Active Business Publishing, στην ετήσια συνάντηση Επιχειρηματικής Αριστείας «Salus Index 2015» στον τομέα Υγεία – Φάρμακο – Ομορφιά σε μια λαμπρή τελετή.

Winners: Novartis - Sanofi – AstraZeneca – Pfizer – J & J Losers: Merck - GlaxoSmithKline

Let's start with the good news.

In 2015, the FDA by its own account approved 45 new drugs, the largest one-year tally since 1996, which wrapped up with a record 53 regulatory OKs.

The new generational high, easily lapping last year's list of 41 approvals, marks a new peak following a surge by the R&D side of the business, which continues to recover from a lengthy period of marked weakness. The FDA has helped, proving more than willing to come through with faster approvals, particularly in oncology. And the science around drug development has improved markedly as our understanding of the genetic drivers of disease continues to make real progress.

But here's the catch: Higher approval numbers don't necessarily translate into market-moving opportunities. Throw another me-too drug into a pack of rivals and even the best sales force can't do much with it, particularly if cheap generics dominate a disease. And in the patent cliff environment that has persisted for several years now, it takes blockbuster gains to make a big difference for the Big Pharma companies that dominate the industry.

So who came out of 2015 a big winner?